<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7046835\results\search\tropicalVirus\results.xml">
  <result pre="doi: 10.3389/fimmu.2020.00287 : Immunology: Perspective Role of T Cells in" exact="Chikungunya" post="Virus Infection and Utilizing Their Potential in Anti-Viral Immunity"/>
  <result pre="is permitted which does not comply with these terms. Abstract" exact="Chikungunya" post="virus (CHIKV) is an arthropod-borne alphavirus that causes hallmark"/>
  <result pre="cells, are known to participate in the pathogenic role of" exact="CHIKV" post="immunopathology. The other T cell subsets, notably CD8+, NKT,"/>
  <result pre="these T cell subsets during acute and chronic phases of" exact="CHIKV" post="infection, and highlight gaps in the current literature. Importantly,"/>
  <result pre="Technology and Research10.13039/501100001348F00018 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Chikungunya" post="virus (CHIKV) belongs to the Togaviridae family and is"/>
  <result pre="Symptoms usually manifest after 4–7 days of incubation period (3)." exact="CHIKV" post="infection has been shown by multiple studies to induce"/>
  <result pre="18). Host innate and adaptive immunity have multifaceted roles in" exact="CHIKV" post="infection. While innate immunity in response to CHIKV infection"/>
  <result pre="roles in CHIKV infection. While innate immunity in response to" exact="CHIKV" post="infection has been well-studied (3, 17, 30), the functions"/>
  <result pre="play significant roles in antiviral immunity, immunomodulation and pathology in" exact="CHIKV" post="infection (24, 28, 31, 32). A better comprehension of"/>
  <result pre="comprehension of the roles each T cell subset play during" exact="CHIKV" post="infection may aid in understanding how to control disease"/>
  <result pre="cells express CD69, CD107a, granzyme B, and perforin during acute" exact="CHIKV" post="infection (17, 33, 34), markers associated with T cell"/>
  <result pre="cell activation. Studies have identified putative CD8 epitopes within the" exact="CHIKV" post="genome in mice and humans (Figure 1) (35, 36)."/>
  <result pre="Despite the apparent abundance, only three HLA-A*0201 CD8 epitopes in" exact="CHIKV" post="6K protein were experimentally validated to trigger CD8 T"/>
  <result pre="different MHCs. Importantly, it remains unclear whether the recognition of" exact="CHIKV" post="epitopes by CD8+ T cells has a role to"/>
  <result pre="open up avenues to employ them as mediators in future" exact="CHIKV" post="vaccines. Figure 1 The list of conserved CD8 epitopes"/>
  <result pre="vaccines. Figure 1 The list of conserved CD8 epitopes in" exact="CHIKV" post="that was identified in silico by others and published"/>
  <result pre="were arranged according to the positions they occupy along the" exact="CHIKV" post="proteome. The immunogenicity scores are determined through the Immune"/>
  <result pre="CD8+ T cell numbers in the joints increased during acute" exact="CHIKV" post="infection. However, they do not protect against CHIKV-associated pathologies"/>
  <result pre="virus (RRV) (38) and Venezuela Equine Encephalomyelitis virus (VEEV) (39)." exact="CHIKV" post="RNA could be detected in the footpad of mice"/>
  <result pre="mice at up to 16 weeks post-challenge, suggesting that chronic" exact="CHIKV" post="infection could persist in the footpad (40). Persistent infection"/>
  <result pre="could persist in the footpad (40). Persistent infection indicates that" exact="CHIKV" post="epitopes could be continuously presented by antigen-presenting cells (APCs)"/>
  <result pre="incapable of eliminating infected cells (41, 42), resulting in perpetual" exact="CHIKV" post="infection. Indeed, the lower levels of CD8+ T cells"/>
  <result pre="of activated marker CD69 suggest an exhausted phenotype in chronic" exact="CHIKV" post="patients (33). In chronic viral (e.g., LCMV and HIV)"/>
  <result pre="a further immune shutdown and more persistent infection. Given that" exact="CHIKV" post="infection is shown to persist in infected mice and"/>
  <result pre="indicating that this is another potential avenue to treat chronic" exact="CHIKV" post="infection. CD4+ T Cells Activated CD4+ T cells have"/>
  <result pre="from exiting the lymphoid organs, also reduces joint pathology in" exact="CHIKV" post="infected mice. In addition, TCR−/− mice, which lack T"/>
  <result pre="T cells are also responsible for the chronic phase of" exact="CHIKV" post="infection. Pathogenic CHIKV-specific CD4+ T cells in CHIKV mouse"/>
  <result pre="phase of CHIKV infection. Pathogenic CHIKV-specific CD4+ T cells in" exact="CHIKV" post="mouse models express T-bet and secrete IFN-γ, markers that"/>
  <result pre="infection, the antiviral effects of IFN-γ are unable to block" exact="CHIKV" post="replication in virus-infected cells due to CHIKV interference with"/>
  <result pre="unable to block CHIKV replication in virus-infected cells due to" exact="CHIKV" post="interference with downstream JAK-STAT signaling (51). These CD4+ T"/>
  <result pre="in the joints of patients during the chronic phase of" exact="CHIKV" post="infection (34). Two CHIKV CD4+ epitopes have been identified"/>
  <result pre="patients during the chronic phase of CHIKV infection (34). Two" exact="CHIKV" post="CD4+ epitopes have been identified in mouse models thus"/>
  <result pre="far, with the cognate CD4+ T cells expressing IFN-γ during" exact="CHIKV" post="infection (32). Despite CD4+ T cells being a cause"/>
  <result pre="T cells being a cause of the pathogenic swelling accompanying" exact="CHIKV" post="infection, they are also crucial in orchestrating the formation"/>
  <result pre="molecules in the latter (52). Thus, when the APCs present" exact="CHIKV" post="epitopes to CD4+ T cells, they become anergic instead"/>
  <result pre="not affected by Tregs (52). Patients with acute and chronic" exact="CHIKV" post="infections were shown to have lower levels of Treg,"/>
  <result pre="Cells The impact of natural killer T (NKT) cells in" exact="CHIKV" post="infection is less well-understood. In patients, acute CHIKV infection"/>
  <result pre="cells in CHIKV infection is less well-understood. In patients, acute" exact="CHIKV" post="infection resulted in an increase of NKT cells in"/>
  <result pre="accumulate in the spleens of mice that are co-infected with" exact="CHIKV" post="and malaria parasites (48). This event is due to"/>
  <result pre="(56–58). Although this strategy of lymphocyte sequestration leads to decreased" exact="CHIKV" post="immunopathology (32, 49), it is not clear how much"/>
  <result pre="T cells are reported to play a protective role against" exact="CHIKV" post="infection (59). These cells do not affect CHIKV virus"/>
  <result pre="role against CHIKV infection (59). These cells do not affect" exact="CHIKV" post="virus replication in the joints. Instead, their absence is"/>
  <result pre="infiltration and result in tissue damage that is observed during" exact="CHIKV" post="infection. However, there is no information on the role"/>
  <result pre="no information on the role of γδ T cells in" exact="CHIKV" post="patients. Thus, the extent of protection these cells offer"/>
  <result pre="offer in human settings remains unclear. Mobilizing T Cells Against" exact="CHIKV" post="in Vaccine Design The roles that each subset of"/>
  <result pre="subset of T cells play in the joint swelling during" exact="CHIKV" post="infection is illustrated in Figure 2. Despite their participation"/>
  <result pre="infection is illustrated in Figure 2. Despite their participation in" exact="CHIKV" post="immunopathology, they have the potential to be included as"/>
  <result pre="neutralize the viruses (23, 28, 60–63). Furthermore, some of the" exact="CHIKV" post="vaccines have been demonstrated to protect against other alphaviruses,"/>
  <result pre="at the lower doses. However, vaccination with recombinant baculovirus expressing" exact="CHIKV" post="envelope proteins caused aged mice (&amp;gt;18 months old) to"/>
  <result pre="aged mice (&amp;gt;18 months old) to become more susceptible to" exact="CHIKV" post="infection (62), which was partly explained by the lower"/>
  <result pre="antibody titers in the aged mice. Although antigenic variations among" exact="CHIKV" post="isolates are not prevalent currently, subtle changes in the"/>
  <result pre="CHIKV isolates are not prevalent currently, subtle changes in the" exact="CHIKV" post="proteome was demonstrated to affect the neutralizing effect of"/>
  <result pre="results in reproductive-competent virus and yet abolishes antibody binding to" exact="CHIKV" post="epitopes may result in future pandemic outbreaks. Figure 2"/>
  <result pre="of the roles each T cell subset play during acute" exact="CHIKV" post="infection. (1) When CHIKV-infected mosquitoes transmit the virus to"/>
  <result pre="virus to its human host (or experimental infection in mice)," exact="CHIKV" post="infects the surrounding cells and creates pro-inflammatory milleu in"/>
  <result pre="cells to the infection site. (3) The APCs that engulfs" exact="CHIKV" post="antigens travel to lymphoid organs, present CHIKV epitopes to"/>
  <result pre="APCs that engulfs CHIKV antigens travel to lymphoid organs, present" exact="CHIKV" post="epitopes to CD4 and CD8 T cells and activate"/>
  <result pre="(81). Hence, the resulting skin TRMs generated can protect against" exact="CHIKV" post="infection from anywhere, regardless of where the virus-infected mosquitoes"/>
  <result pre="release the virus into the host. In the event where" exact="CHIKV" post="penetrates the skin barrier and infect the surrounding cells"/>
  <result pre="virus-infected cells before the disease is established (82, 83). Moreover," exact="CHIKV" post="exposure should further boost pre-existing anti-CHIKV immune response and"/>
  <result pre="memory T cells (79, 80). Over time, repeated exposure of" exact="CHIKV" post="should lead to further CHIKV-specific skin TRM accumulation all"/>
  <result pre="TRM accumulation all over the skin, with no establishment of" exact="CHIKV" post="pathology. The geographical range of mosquitoes that transmit the"/>
  <result pre="increase in the future due to climate change (84). Moreover," exact="CHIKV" post="shares some homology with other alphaviruses with the potential"/>
  <result pre="(85–89). This shift may ultimately lead to the spread of" exact="CHIKV" post="and other alphaviruses and cause future epidemics. However, as"/>
  <result pre="(90) and Powers et al. (91), the close homology between" exact="CHIKV" post="and other viruses within the family of alphaviruses suggest"/>
  <result pre="in the United States (92). Concluding Remarks The re-emergence of" exact="CHIKV" post="underscores the need for effective vaccine strategies to prevent"/>
  <result pre="the need for effective vaccine strategies to prevent further global" exact="CHIKV" post="dissemination. In immunological naïve individuals, CHIKV infection puts them"/>
  <result pre="to prevent further global CHIKV dissemination. In immunological naïve individuals," exact="CHIKV" post="infection puts them at risk of having their immune"/>
  <result pre="them at risk of having their immune system manipulated toward" exact="CHIKV" post="pathology and virus persistence. An optimal vaccine against CHIKV"/>
  <result pre="toward CHIKV pathology and virus persistence. An optimal vaccine against" exact="CHIKV" post="invokes not only humoral response, but more importantly, localized"/>
  <result pre="anti-CHIKV TRMs have the potential to react to more conserved" exact="CHIKV" post="epitopes (which may also be conserved in closely related"/>
  <result pre="of chikungunya virus. Nat Rev Microbiol. (2010) 8:491–500. 10.1038/nrmicro236820551973 4.StaplesEJBreimanRFPowersAM." exact="Chikungunya" post="fever: an epidemiological review of a re-emerging infectious disease."/>
  <result pre="re-emerging infectious disease. Clin Infect Dis. (2009) 49:942–8. 10.1086/60549619663604 5.NimmannityaSHalsteadSCohenSMargiottaM." exact="Dengue" post="and chikungunya virus infection in man in Thailand, 1962–1964."/>
  <result pre="Am J Trop Med Hygiene. (1969) 18:954–71. 10.4269/ajtmh.1969.18.9545355242 6.ThaikrueaLCharearnsookOReanphumkarnkitSDissomboonPPhonjanRRatchbudSet al.." exact="Chikungunya" post="in Thailand: a re-emerging disease?Southeast Asian J Trop Med"/>
  <result pre="2004. Am J Trop Med Hyg. (2008) 78:333–7. 10.4269/ajtmh.2008.78.33318256441 13.CoffeyLLFaillouxA-BWeaverSC." exact="Chikungunya" post="virus–vector interactions. Viruses. (2014) 6:4628–63. 10.3390/v611462825421891 14.PowersALogueC. Changing patterns"/>
  <result pre="colony-stimulating factor. J Infect Dis. (2011) 203:149–57. 10.1093/infdis/jiq04221288813 19.GardnerJAnrakuILeTTLarcherTMajorLRoquesPet al.." exact="Chikungunya" post="virus arthritis in adult wild-type mice. J Virol. (2010)"/>
  <result pre="adult wild-type mice. J Virol. (2010) 84:8021–32. 10.1128/JVI.02603-0920519386 20.LabadieKLarcherTJoubertCManniouiADelacheBBrochardPet al.." exact="Chikungunya" post="disease in nonhuman primates involves long-term viral persistence in"/>
  <result pre="T cell response and advancement of epitope based immunotherapy for" exact="CHIKV" post="infection. Infect Gene Evol. (2015) 31:118–26. 10.1016/j.meegid.2015.01.01725643869 36.WaheedYSafiSNajmiMAzizHImranM. Prediction"/>
  <result pre="in mice. Life Sci Alliance. (2019) 2:e201900298. 10.26508/lsa.20190029830665948 51.FrosJJLiuWProwNAGeertsemaCLigtenbergMVanlandinghamDLet al.." exact="Chikungunya" post="virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT"/>
 </snippets>
</snippetsTree>
